Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs Kraft Heinz Co (KHC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs Kraft Heinz Co — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $112.02 (market cap $12.58B), while Kraft Heinz Co trades at $22.16 (market cap $26.66B). The key difference: Kraft Heinz Co is far larger — about 2.1× Halozyme Therapeutics Inc. Common Stock's market cap, and Kraft Heinz Co pays a 7.12% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and Kraft Heinz Co for 129 Days on average.
| HALO | KHC | |
|---|---|---|
Market Cap | $12.58B | $26.66B |
Volume | 2,179,278 | 31,300,109 |
Sector | Health | Consumer Staples |
52-Week High | $115.22 | $27.62 |
52-Week Low | $61.63 | $21.21 |
Typical Hold Time | 1 Days | 129 Days |
Enterprise Value | $14.49B | $42.98B |
Dividend Yield | — | 7.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Kraft Heinz (KHC) trades at $22.08, up 0.45% on the day, with a bearish technical outlook despite recent earnings beats. The stock shows mixed signals with a low P/E of 13.04 and P/B of 0.74, but negative profitability metrics including a net income margin of -13.64% and ROE of -8.78% reflect challenges from a recent $5.85B net loss in 2025. The company maintains strong operating cash flow of $4.46B and a dividend yield near 6.5%, supported by ongoing brand reinvestment efforts.
The investment outlook is cautious; valuation discounts may attract value investors, but persistent volume declines and high debt pose significant risks. Analyst consensus is mixed with a $24.50 price target, yet only 11.43% recommend buying. Key catalysts include successful turnaround execution and new product launches, though competitive pressures and margin recovery remain critical hurdles for sustained shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About Kraft Heinz Co
In July 2015, Kraft merged with Heinz to create the third-largest food and beverage manufacturer in North America behind PepsiCo and Nestle and the fifth-largest player in the world. Beyond its namesake brands, the combined firm's portfolio includes Oscar Mayer, Velveeta, and Philadelphia. Outside North America, the firm's global reach includes a distribution network in Europe and emerging markets that drive around one fifth of its consolidated sales base, as its products are sold in more than 190 countries and territories.
Read more on KHC →
